Who Benefits Most from Liver Elastography? Key Indications and Results

Short answer: Liver elastography is a non-invasive measurement of tissue stiffness (in kPa) and—in many devices—the CAP steatosis indicator (dB/m). It most often provides the greatest informational value for people with NAFLD/NASH and features of metabolic syndrome, chronic HBV/HCV, regular exposure to alcohol or hepatotoxic medications, as well as patients with “normal enzymes” but high risk based on their medical history.

The liver can remain diseased without symptoms for a long time, while biochemical abnormalities appear late or may be temporary. Enzyme activities alone do not indicate how advanced fibrosis is. Here, 2D ultrasound and ALT/AST/GGT testing can be supplemented by elastography, which provides numerical parameters of stiffness and steatosis.

What Is Elastography and What Does It Measure?

Liver elastography uses short mechanical waves generated by the probe that travel through the tissue. Their propagation speed increases with stiffness, and the result is presented in kPa. Many devices also calculate the CAP indicator (dB/m), which correlates with the degree of steatosis. A series of readings is obtained, with the median being key; quality is assessed using IQR/median (variability/median), as well as the reported number of acquisitions and the percentage of successful measurements. Typically, the aim is to obtain several successful acquisitions, an acceptable IQR/median ratio, and consistency with the clinical picture.

Groups Most Likely to Benefit Informationally

Metabolic Profile and NAFLD/NASH

Visceral obesity, insulin resistance, an unfavorable TG/HDL profile, and elevated blood glucose promote NAFLD and progression to NASH.
CAP enables a numerical assessment of steatosis, while kPa indicates the extent of fibrosis, including when enzyme levels are unclear or periodically normal.
Its value increases when monitoring the trend in results over time, for example during lifestyle changes or treatment of coexisting metabolic disorders.
Regardless of the result, interpretation should take 2D ultrasound and factors that may interfere with the measurement into account.

Chronic HBV/HCV

In chronic HBV/HCV infections, elastography enables non-invasive monitoring of changes in liver tissue stiffness.
The result complements 2D ultrasound (structure, focal lesions) and ALT/AST/GGT testing (process activity), helping assess the dynamics of fibrosis.
The trend in results before and after antiviral treatment, as well as consistency with biochemical data, is important.
Acquisition quality (IQR/median, number of acquisitions) determines the reliability of the conclusions.

Exposure to Alcohol and Hepatotoxic Medications

In people regularly exposed to alcohol or taking hepatotoxic medications, elastography helps assess the liver tissue, including when enzyme levels fluctuate.
Factors that may temporarily elevate kPa should be taken into account, such as acute inflammation, cholestasis, or hepatic congestion.
The numerical result can help distinguish temporary from persistent changes, especially when successive measurements are analyzed.
The assessment is made in the context of other tests and the medical history.

Autoimmune/Cholestatic Diseases and Hemochromatosis

In autoimmune hepatitis and cholestatic liver diseases, an early numerical assessment of fibrosis progression is useful.
In hemochromatosis, stiffness measurement can support decisions about further diagnosis and monitoring of the course of the disease.
Results should be interpreted taking the etiology, 2D ultrasound, and biochemical parameters into account.
Acquisition quality remains a prerequisite for reliable interpretation.

“Normal Enzymes” Despite High Risk

A family history, lifestyle factors, or coexisting metabolic disorders may indicate elevated risk despite normal ALT/AST/GGT levels.
In such situations, liver elastography organizes the overall picture by providing objective numbers (kPa, CAP) that are discussed in the clinical context.
Repeat measurements under similar conditions make it easier to identify a trend, which is more significant than a single reading.
Consistency with 2D ultrasound and other tests increases the reliability of the conclusions.

Elastography and Other Methods: Why They Complement Each Other

2D ultrasound assesses structure, echogenicity, possible focal lesions, and signs of portal hypertension.
Liver elastography provides numbers describing fibrosis (kPa) and steatosis (CAP), helping organize risk.
ALT/AST/GGT mainly indicate process activity, but do not independently determine the extent of fibrosis.

Preparation and Acquisition Quality

In practice, a short period without food before the examination, calm breathing, and positioning in accordance with the procedure are recommended. In people with obesity, selecting the appropriate probe and focus depth is important. The quality report usually includes the number of acquisitions, the percentage of successful measurements, and IQR/median. Lower variability relative to the median and a greater number of successful attempts support reliability. To assess changes over time, measurements should be performed under comparable conditions (time of day, preparation, and the same method).

Interfering Factors and Limitations

A meal immediately before the measurement may affect kPa and CAP values.
Acute inflammation, cholestasis, and hepatic congestion may temporarily elevate the assessed stiffness.
In obesity and with a greater focus depth, an alternative probe may be required, improving acquisition quality.
Elastography does not replace a complete clinical assessment; interpretation should take the 2D ultrasound image, biochemistry, and medical history into account.

How to Use the Results in Practice

A single reading provides point-in-time information and may be sensitive to examination conditions. A series of measurements enables assessment of the trend in results, which better reflects the course of fibrosis or the response to an intervention. For comparability, a similar time of day, comparable preparation, and the same measurement technology are recommended. In the report, it is worth noting kPa, CAP, IQR/median, the percentage of successful measurements, and the number of acquisitions, and then discussing them in the context of the remaining data.

Frequently Asked Questions (FAQ)

Does elastography replace 2D ultrasound or a biopsy?

No. Elastography usually complements 2D ultrasound and blood tests. A biopsy may be considered in unclear cases or when histopathological verification is needed, depending on the clinical picture.

Is CAP the percentage of fat?

No. CAP is an indicator expressed in dB/m, interpreted within ranges proposed for a given technology and population. It does not directly represent the percentage of fat content in hepatocytes.

Does a high kPa value always mean cirrhosis?

No. Elevated kPa values may result from many causes, including temporary conditions. The diagnosis of advanced fibrosis depends on combining the result with acquisition quality, disease etiology, and other tests.

The scope of the examination, reporting method, and interpretation of the parameters—kPa, CAP, IQR/median, and the number of acquisitions—are described in detail on the page about liver imaging examinations. See the method and preparation description: liver elastography Warsaw.

Summary at a Glance

People with NAFLD/NASH and features of metabolic syndrome, patients with chronic HBV/HCV, exposure to alcohol or hepatotoxic medications, and those with elevated risk despite “normal enzymes” derive the greatest informational benefit from elastography. The kPa parameter reflects stiffness associated with fibrosis, while CAP reflects steatosis in dB/m. The result should be combined with 2D ultrasound and ALT/AST/GGT, with assessment of quality (IQR/median, number of acquisitions) and analysis of the trend over time.

This material is for informational purposes and does not replace medical advice.

Who Benefits Most from Elastography?